Screener
Ionis Pharmaceuticals IONS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
| Accumulated deficit | (2,838,369) | (2,631,195) |
| Total stockholders' equity | 439,737 | 489,089 |
| Total liabilities and stockholders’ equity | $$2,994,501 | 3,523,836 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's total equity?
- Ionis Pharmaceuticals (IONS) reported total equity of $439.74M in Q2 2026.
- How has Ionis Pharmaceuticals's total equity changed year-over-year?
- Ionis Pharmaceuticals's total equity decreased by 30.4% year-over-year, from $631.72M to $439.74M.
- What is the long-term trend for Ionis Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total equity has grown at a -10.3% compound annual growth rate (CAGR), from $843.35M to $489.09M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Ionis Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude